European Heart Journal Advance Access originally published online on April 18, 2006
European Heart Journal 2006 27(10):1166-1173; doi:10.1093/eurheartj/ehi877
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
1 Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, University Hospital, 751 85 Uppsala, Sweden
2 Lilly Research Centre Ltd., Windlesham, Surrey, UK
3 Eli Lilly and Company, Indianapolis, IN, USA
4 Clinical Pharmacology and Biostatistics Department, Sankyo Co. Ltd., Tokyo, Japan
5 Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Sweden
Received 3 September 2005; revised 6 March 2006; accepted 23 March 2006; online publish-ahead-of-print 18 April 2006.
* Corresponding author. Tel: +46 18 611 00 00; fax: +46 18 50 66 38. E-mail address: lars.wallentin{at}ucr.uu.se
Aims This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD).
Methods and results Subjects (n=101) were randomly assigned to the following loading dose (LD) (day 1)/maintenance dose (MD) (days 2–28) combinations: prasugrel, 40 mg/5 mg; 40 mg/7.5 mg; 60 mg/10 mg; 60 mg/15 mg; or clopidogrel, 300 mg/75 mg. Turbidometric platelet aggregation was measured at multiple timepoints during the study. At 4 h after dosing, with 20 µM ADP, both prasugrel LDs achieved significantly higher mean IPA levels (60.6% and 68.4 vs. 30.0%, respectively; all P<0.0001) and lower percentage (3 vs. 52%, P<0.0001) of pharmacodynamic non-responders (defined as IPA <20%) than clopidogrel. Prasugrel 10 and 15 mg MDs achieved consistently higher mean IPA than clopidogrel 75 mg at day 28 (all P<0.0001). At pre-MD on day 28, there were no non-responders in the 10 and 15 mg prasugrel group, compared with 45% in the clopidogrel group (P=0.0007).
Conclusion In this population, prasugrel (40–60 mg LD and 10–15 mg MD) achieves greater IPA and a lower proportion of pharmacodynamic non-responders compared with the approved clopidogrel dosing.
Key Words: Prasugrel • CS-747 • Thienopyridine • Clopidogrel • Platelets • Trials
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Cattaneo Fast, potent, and reliable inhibition of platelet aggregation Eur. Heart J. Suppl., December 1, 2009; 11(suppl_G): G9 - G13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. RAYMOND and V. MENON Dual antiplatelet therapy in coronary artery disease: A case-based approach Cleveland Clinic Journal of Medicine, November 1, 2009; 76(11): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hagihara, M. Kazui, A. Kurihara, M. Yoshiike, K. Honda, O. Okazaki, N. A. Farid, and T. Ikeda A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel Drug Metab. Dispos., November 1, 2009; 37(11): 2145 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes N. Engl. J. Med., September 10, 2009; 361(11): 1045 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano Antithrombotics in acute coronary syndromes. J. Am. Coll. Cardiol., September 8, 2009; 54(11): 969 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet and G. Montalescot Review: Platelet Function Testing and Implications for Clinical Practice Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 157 - 169. [Abstract] [PDF]
|
|
|
|
|
|
M. O'Donoghue, E. M. Antman, E. Braunwald, S. A. Murphy, P. G. Steg, A. Finkelstein, W. F. Penny, V. Fridrich, C. H. McCabe, M. S. Sabatine, et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Analysis. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wallentin P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Wrishko, C. S. Ernest II, D. S. Small, Y. G. Li, G. J. Weerakkody, J. R. Riesmeyer, W. L. Macias, S. Rohatagi, D. E. Salazar, E. M. Antman, et al. Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON-TIMI 38 J. Clin. Pharmacol., August 1, 2009; 49(8): 984 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur. Heart J., July 2, 2009; 30(14): 1744 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michelson, A. L. Frelinger III, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur. Heart J., July 2, 2009; 30(14): 1753 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Morrow, S. D. Wiviott, H. D. White, J. C. Nicolau, E. Bramucci, S. A. Murphy, M. P. Bonaca, C. T. Ruff, B. M. Scirica, C. H. McCabe, et al. Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38: An Application of the Classification System From the Universal Definition of Myocardial Infarction Circulation, June 2, 2009; 119(21): 2758 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price Bedside Evaluation of Thienopyridine Antiplatelet Therapy Circulation, May 19, 2009; 119(19): 2625 - 2632. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Smout and G. Stansby Surgery and antiplatelet agents: what are the risks? Clin Risk, May 1, 2009; 15(3): 101 - 105. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Veverka and J. M. Hammer Prasugrel: A New Thienopyridine Inhibitor Journal of Pharmacy Practice, April 1, 2009; 22(2): 158 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Hopkins and M. Limacher The Role of Aspirin in Cardiovascular Disease Prevention in Women American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 123 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Scott, R. M Norwood, and D. Parra P2Y12 Inhibitors in Cardiovascular Disease: Focus on Prasugrel Ann. Pharmacother., January 1, 2009; 43(1): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Erlinge, C. Varenhorst, O. O. Braun, S. James, K. J. Winters, J. A. Jakubowski, J. T. Brandt, A. Sugidachi, A. Siegbahn, and L. Wallentin Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1968 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Aleil, L. Jacquemin, F. De Poli, M. Zaehringer, J.-P. Collet, G. Montalescot, J.-P. Cazenave, M.-C. Dickele, J.-P. Monassier, and C. Gachet Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention: Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 631 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part I: Primary Percutaneous Coronary Intervention Circulation, July 29, 2008; 118(5): 538 - 551. [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Riley, M. J. Tafreshi, and S. L. Haber Prasugrel: A novel antiplatelet agent Am. J. Health Syst. Pharm., June 1, 2008; 65(11): 1019 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price How to react to high platelet reactivity?: reply Eur. Heart J., June 1, 2008; 29(11): 1471 - 1472. [Full Text] [PDF]
|
|
|
|
|
|
J.J.J. van Giezen Optimizing platelet inhibition Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D23 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wallentin Dual antiplatelet therapy in the drug-eluting stent era Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D38 - D44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur. Heart J., April 2, 2008; 29(8): 992 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Small, N. A. Farid, C. D. Payne, G. J. Weerakkody, Y. G. Li, J. T. Brandt, D. E. Salazar, and K. J. Winters Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel J. Clin. Pharmacol., April 1, 2008; 48(4): 475 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Michelson P2Y12 Antagonism: Promises and Challenges Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang and B. Kanna A double blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur. Heart J., February 1, 2008; 29(3): 423 - 424. [Full Text] [PDF]
|
|
|
|
|
|
L. Wallentin, C. Varenhorst, S. James, D. Erlinge, O. O Braun, J. A. Jakubowski, A. Sugidachi, K. J. Winters, and A. Siegbahn Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur. Heart J., January 1, 2008; 29(1): 21 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Farid, C. D. Payne, C. S. Ernest II, Y. G. Li, K. J. Winters, D. E. Salazar, and D. S. Small Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans J. Clin. Pharmacol., January 1, 2008; 48(1): 53 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Gitt and A. Betriu Antiplatelet therapy in acute coronary syndromes Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A4 - A12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand When and how to discontinue antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A35 - A41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial Circulation, December 18, 2007; 116(25): 2923 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.-J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes N. Engl. J. Med., November 15, 2007; 357(20): 2001 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Campo, M. Valgimigli, D. Gemmati, G. Percoco, L. Catozzi, A. Frangione, F. Federici, F. Ferrari, M. Tebaldi, S. Luccarelli, et al. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?: Evidence From a Clopidogrel-to-Ticlopidine Crossover Study J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1132 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Weerakkody, J. A. Jakubowski, J. T. Brandt, C. D. Payne, H. Naganuma, and K. J. Winters Greater Inhibition of Platelet Aggregation and Reduced Response Variability With Prasugrel Versus Clopidogrel: An Integrated Analysis Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 205 - 212. [Abstract] [PDF]
|
|
|
|
|
|
C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Husted New developments in oral antiplatelet therapy Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D20 - D27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Farid, R. L. Smith, T. A. Gillespie, T. J. Rash, P. E. Blair, A. Kurihara, and M. J. Goldberg The Disposition of Prasugrel, a Novel Thienopyridine, in Humans Drug Metab. Dispos., July 1, 2007; 35(7): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster The Year in Atherothrombosis J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1740 - 1749. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T. A. Bass, and M. A. Costa Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1505 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Wiper and D. H Roberts Stent thrombosis: Consider also low response to antiplatelets BMJ, January 13, 2007; 334(7584): 57 - 57. [Full Text] [PDF]
|
|
|
|
|
|
M. O'Donoghue and S. D. Wiviott Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All? Circulation, November 28, 2006; 114(22): e600 - e606. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Beitelshees and H. L. McLeod Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1681 - 1683. [Full Text] [PDF]
|
|